IS-001 Injection in Patients Undergoing Robotic-Assisted Colorectal Surgery
Intuitive Surgical · NCT07346066
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 16–75 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 3
- Target enrollment
- 146
- US sites recruiting
- 6
- Study start
- May 14, 2026
- Record last updated
- August 5, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This study evaluates the safety and efficacy of intravenous injection of IS-001 to aid in intraoperative ureter structure delineation
Being studied: filricianine
Conditions: Ureter Injury
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Male and female participants between the ages of 16 and 75, inclusive
- Participant is scheduled to undergo robotic-assisted colectomy using the da Vinci X/Xi Surgical System with SFF Fluorescence Imaging Exclusion Criteria
- Participant is pregnant or nursing 2. Participant has known current acute or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection 3. Participant has any of the following screening laboratory values: eGFR \< 30 mL/min/1.73 m2
- Aspartate aminotransferase (AST) ≥ 2.5 × ULN
- Alanine aminotransferase (ALT) ≥ 2.5 × ULN
- Total Bilirubin > 2mg/dL 4. Participant has any concomitant non-colorectal cancer 5. Participant has any circumstances that, in the judgment of the Investigator, might make them not a suitable candidate for the study 6. Participants have already been enrolled in another investigational drug or device study within the past 6 months 7. Participants with known or suspected hypersensitivity to indocyanine green (ICG) or any components of the formulation used 8. Participant is expected to receive or has received other methods for ureter identification during the surgery (e.g., ureteral stent placement, illuminated catheters, retrograde ICG injections) before the administration of IS-001 9. The duration of the surgery is expected to be less than 90 minutes as determined during preoperative planning.
Recruiting US locations
Hoag Memorial Hospital Presbyterian
Newport Beach, CA 92663
Site contact: Vianh Truong · 949-764-5597 · vianh.truong@hoag.org
Yale New Haven Hospital
New Haven, CT 06510
Site contact: Kyra Jersey · 203-688-4242 · kyra.jersey@yale.edu
Orlando Health
Orlando, FL 32806
Site contact: Patty Camacho · 321-842-4130 · Patty.Camacho@orlandohealth.com
Mountain View Hospital
Las Vegas, NV 89128
Site contact: Coral Rodriguez · 702-255-5000 · coral.rodriguez@hchealthcare.com
St David's North Austin Medical Center
Austin, TX 78758
Site contact: Krishna Saini · 5125448070 · Krishna.Saini@stdavids.com
HCA Houston Healthcare Medical Center
Houston, TX 77004
Site contact: Jimena Alcocer-Barrios · 713-527-5000 · jalcocerbarrios@houstoncolon.com
Study contacts (from the official record)
- Clinical Project Manager · 4085232100 · info.is-001@intusurg.com